WebManagement Team — Imugene (ASX: IMU) Dr Nick Ede Chief Technology Officer Dr Ede has over 25 years’ peptide vaccine and drug development. He was formerly CEO of Adistem and CEO of Mimotopes. Prior to that he was VP Chemistry at Chiron (now Novartis), and has been a Research Fellow at the CRC for Vaccine Technology. WebIUGNF Complete Imugene Ltd. stock news by MarketWatch. View real-time stock prices …
Imugene Limited (IUGNF) Stock Price & News - Google Finance
WebFeb 10, 2024 · Imugene Ltd (ASX:IMU, OTC:IUGNF) has once again locked in international property protection for its assets. The US Patent and Trademark Office (USPTO) has given Imugene a Notice of Allowance related to its B-cell activating immunotherapy PD1-Vaxx (patent application number 16/498,929). WebShares Outstanding Number of shares that are currently held by investors, including … fitzpatrick accounting slo
Imugene Limited (ASX:IMU) - Shares, Dividends & News
WebAug 4, 2024 · Imugene Limited is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate... WebMar 22, 2024 · Imugene Limited is an Australia-based clinical-stage immuno-oncology company. The Company is engaged in developing a range of new immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. ... Share price information may be rounded up/down and therefore not entirely accurate. FT … WebApr 12, 2024 · Discover historical prices for IMU.AX stock on Yahoo Finance. View daily, weekly or monthly formats back to when Imugene Limited stock was issued. fitzpatrick agency bridgeport ct